Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Profit After Tax (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Profit After Tax for 17 consecutive years, with $746860.0 as the latest value for Q1 2026.

  • Quarterly Profit After Tax rose 124.52% to $746860.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$3.3 million through Jan 2026, down 116.2% year-over-year, with the annual reading at $30.7 million for FY2025, 9084.98% up from the prior year.
  • Profit After Tax for Q1 2026 was $746860.0 at PharmaCyte Biotech, up from -$7.4 million in the prior quarter.
  • The five-year high for Profit After Tax was $23.4 million in Q3 2024, with the low at -$8.4 million in Q3 2025.
  • Average Profit After Tax over 5 years is $553447.7, with a median of -$811290.0 recorded in 2022.
  • The sharpest move saw Profit After Tax soared 1165.95% in 2024, then plummeted 404.78% in 2025.
  • Over 5 years, Profit After Tax stood at -$1.9 million in 2022, then skyrocketed by 248.36% to $2.8 million in 2023, then tumbled by 152.67% to -$1.5 million in 2024, then tumbled by 404.78% to -$7.4 million in 2025, then soared by 110.07% to $746860.0 in 2026.
  • According to Business Quant data, Profit After Tax over the past three periods came in at $746860.0, -$7.4 million, and -$8.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.